Reyes Financial Architecture Inc. Acquires New Stake in ICU Medical, Inc. $ICUI

Reyes Financial Architecture Inc. bought a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 27,035 shares of the medical instruments supplier’s stock, valued at approximately $4,339,000. ICU Medical accounts for approximately 2.7% of Reyes Financial Architecture Inc.’s holdings, making the stock its 6th largest holding.

A number of other institutional investors also recently made changes to their positions in ICUI. Kirr Marbach & Co. LLC IN grew its position in shares of ICU Medical by 0.6% during the third quarter. Kirr Marbach & Co. LLC IN now owns 45,641 shares of the medical instruments supplier’s stock worth $7,326,000 after buying an additional 287 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of ICU Medical by 1.3% in the third quarter. Nisa Investment Advisors LLC now owns 6,088 shares of the medical instruments supplier’s stock worth $977,000 after buying an additional 79 shares during the last quarter. Reinhart Partners LLC. increased its stake in shares of ICU Medical by 2.3% in the third quarter. Reinhart Partners LLC. now owns 322,095 shares of the medical instruments supplier’s stock worth $51,699,000 after buying an additional 7,327 shares during the last quarter. Versant Capital Management Inc increased its stake in shares of ICU Medical by 26.2% in the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 65 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in ICU Medical in the second quarter valued at $3,744,000. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other ICU Medical news, VP Virginia Sanzone sold 4,856 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the completion of the sale, the vice president owned 14,604 shares in the company, valued at $2,463,548.76. The trade was a 24.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Elisha W. Finney sold 378 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total transaction of $68,977.44. Following the sale, the director owned 4,871 shares of the company’s stock, valued at approximately $888,860.08. The trade was a 7.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 21,830 shares of company stock valued at $3,905,003 over the last three months. 2.10% of the stock is currently owned by company insiders.

ICU Medical Price Performance

Shares of ICUI opened at $168.33 on Friday. The firm has a market cap of $4.21 billion, a price-to-earnings ratio of 142.65, a PEG ratio of 2.02 and a beta of 0.86. The stock has a 50 day moving average of $166.06 and a 200-day moving average of $150.73. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. ICU Medical, Inc. has a 52 week low of $113.37 and a 52 week high of $192.85.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The business had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The business’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the business earned $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts forecast that ICU Medical, Inc. will post 7.22 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Piper Sandler raised their price objective on shares of ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings raised shares of ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Needham & Company LLC boosted their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $200.00 target price on shares of ICU Medical in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $192.80.

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.